Avalo Therapeutics (AVTX) appointed Jennifer Riley as Chief Strategy Officer, effective January 1. Riley has over 20 years of leadership experience in the biotechnology and pharmaceutical industries. Most recently, she founded Northbrook Consulting. Previously, she held senior leadership roles at Biogen, including Vice President of Program Leadership and Management, overseeing the strategy and launch readiness for its hemophilia portfolio.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Avalo Therapeutics initiated with a Buy at BTIG
- Avalo Therapeutics initiated with a Buy at Lucid Capital
- Avalo Therapeutics (AVTX) Is a Potential Hidden Gem with Significant Risk
- Avalo Therapeutics receives $69.4M in proceeds from exercise of warrants
- Avalo Therapeutics reports Q3 EPS ($2.83) vs ($22.83) last year